Pages that link to "Q46530085"
Jump to navigation
Jump to search
The following pages link to Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial (Q46530085):
Displaying 13 items.
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Q24235718) (← links)
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Q24240522) (← links)
- Rosiglitazone for type 2 diabetes mellitus (Q24243875) (← links)
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Q24244739) (← links)
- Factors associated with results and conclusions of trials of thiazolidinediones (Q28475588) (← links)
- Metabolic syndrome: from global epidemiology to individualized medicine (Q36939259) (← links)
- Optimizing combination treatment in the management of type 2 diabetes (Q37031367) (← links)
- Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis (Q37789491) (← links)
- Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach (Q50646275) (← links)
- Evidence Based Laboratory Medicine in the Diagnosis of Metabolic Syndrome. (Q55283962) (← links)
- Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway (Q60911519) (← links)
- Effect of the Interaction between Obstructive Sleep Apnea and Lipoprotein(a) on Insulin Resistance: A Large-Scale Cross-Sectional Study (Q64067159) (← links)
- Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus (Q93174864) (← links)